AGM
FULC icon

Alpine Global Management’s Fulcrum Therapeutics FULC Stock Holding History

Alpine Global Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-59,983
Closed -$372K – 262
2024
Q2 		$372K Buy
+59,983
New +$454K 0.06% 213
2023
Q1 		– Sell
-16,073
Closed -$117K – 259
2022
Q4 		$117K Buy
+16,073
New +$105K 0.04% 187
2022
Q1 		– Sell
-20,905
Closed -$370K – 546
2021
Q4 		$370K Buy
+20,905
New +$414K 0.05% 421

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Alpine Global Management's FULC Position: Q3 2024 in Review

Alpine Global Management sold out of Fulcrum Therapeutics (FULC) in Q3 2024, closing a stake of 59,983 shares — an estimated $372K sold.

Alpine Global Management first reported a position in FULC in Q4 2021 and held it in 3 quarters. The position peaked at $372K in Q2 2024. 130 funds tracked by Wall St. Rank hold FULC as of Q3 2024.

  • Alpine Global Management reported no remaining Fulcrum Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 59,983 Fulcrum Therapeutics shares in Q3 2024, an estimated $372K.
  • Alpine Global Management first reported a position in Fulcrum Therapeutics in Q4 2021 and held it in 3 quarters.
  • Alpine Global Management's Fulcrum Therapeutics position peaked at $372K in Q2 2024.
  • 130 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.